PERIMETER MED IMAGING AI - PYNKF STOCK NEWS

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) reported its second quarter results on August 24, 2022. The company anticipates 10-20 commercial installations for its S-Series OCT device, reflecting increased market opportunities. Operating expenses amounted to $6.3 million, up from $3.1 million a year prior, while the net loss narrowed to $366,296 compared to $3.2 million in Q2 2021. Cash and cash equivalents stood at $44.97 million. The company is progressing in its pivotal clinical trial for the B-Series OCT system, with seven out of eight sites activated.

Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) will announce its second quarter 2022 financial results after U.S. markets close on August 24, 2022. A conference call is scheduled for the same day at 5:00 PM ET, featuring key executives including CEO Jeremy Sobotta and CFO Chris Scott. Participants can join via dial-in or through a live webcast, with playback available for 14 days post-call. The company focuses on enhancing cancer surgery through innovative imaging solutions, including FDA-cleared systems for real-time visualization of excised tissues.

Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) has announced the first commercial installation of its Perimeter S-Series OCT system at Pavilion Surgery Center in Orange, California. This advanced medical imaging technology enables real-time margin visualization during surgeries, enhancing breast cancer procedures. Cleared by the FDA in 2021, the system offers 10x higher resolution than standard imaging techniques, potentially improving patient outcomes and reducing healthcare costs. Leading surgeons are already utilizing the system to ensure clean margins during surgeries.

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) announces the appointment of Anantha Kancherla to its Board of Directors, effective immediately. Kancherla brings experience from leading tech firms like Microsoft and Facebook, which CEO Jeremy Sobotta believes will enhance their AI technology development. Perimeter's S-Series imaging technology is commercially available in the U.S., while the B-Series with AI is undergoing pivotal clinical trials. This leadership change comes at a crucial time for the company as it aims to innovate in cancer surgery imaging.

Perimeter Medical Imaging AI has appointed Chris Scott as the new Chief Financial Officer, effective immediately. Scott brings extensive experience in the medtech sector, having previously served as CFO at iRadimed Corporation (NASDAQ: IRMD) and successfully led them through an IPO, increasing their market cap from $10 million to $600 million. The company is well-positioned with a strong balance sheet and is focused on further developing its S-Series OCT and next-gen AI technology.

Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) reported its Q1 2022 financials, highlighting a net loss of $6.45 million compared to $4.02 million last year. Operating expenses rose to $4.85 million, up from $3.82 million. The company reaffirms its 2022 installation goal of 15-20 units of the S-Series OCT, backed by gross proceeds of $48.7 million from a recent financing. The B-Series OCT, currently in clinical validation, aims to improve intraoperative margin assessment in breast cancer surgery.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK, OTC:PYNKF) announced participation in the ROTH Canada Showcase Day on May 17, 2022, in New York, NY. The company aims to transform cancer surgery using advanced imaging tools. A presentation will be led by CEO Jeremy Sobotta at 12:00 p.m. ET. Investors can register for the webcast here.

Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF) announced a conference call to discuss its financial results for the year ending December 31, 2021, scheduled for May 3, 2022 at 5:00 pm ET. The call aims to provide insights into the company's performance in transforming cancer surgery with advanced imaging tools. Investors can join the call via phone or audio webcast.

Perimeter Medical Imaging AI (OTC:PYNKF) reported its financial results for the year ended December 31, 2021, highlighting key developments in its commercial and clinical strategies. The Company achieved its first S-Series OCT installation, with guidance for 15-20 installations in 2022. Financially, operating expenses rose to $16.15 million, with a net loss of $16.64 million. Post-year-end, Perimeter raised approximately $48.7 million to strengthen its balance sheet. The Company is focused on ongoing clinical trials and expanding its product offerings to enhance patient outcomes.